Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
Products for Apoptosis
- Caspase(99)
- 14.3.3 Proteins(1)
- Apoptosis Inducers(43)
- Bax(7)
- Bcl-2 Family(120)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(66)
- MDM2(12)
- p53(123)
- PC-PLC(4)
- PKD(7)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(145)
- Other Apoptosis(883)
- APC(6)
- PD-1/PD-L1 interaction(90)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(31)
- Cat.No. 产品名称 Information
-
GC18136
BH3I-1
BHI1; BH 3I1
An inhibitor of anti-apoptotic Bcl-2 proteins -
GC17603
PS-1145
IKK Inhibitor X
An IKKβ inhibitor -
GC11469
TASIN-1
An inhibitor of truncated APC
-
GC12621
S63845
An Mcl-1 inhibitor
-
GC14929
Monastrol
(±)-Monastrol
Reversible inhibitor of the motor protein Eg5 -
GC10265
Manumycin A
手霉素A
A farnesyltransferase inhibitor with antitumor activity -
GC14154
(±)-Nutlin-3
REL-4-[[(4R,5S)-4,5-双(4-氯苯基)-4,5-二氢-2-[4-甲氧基-2-(1-甲基乙氧基)苯基]-1H-咪唑-1-基]羰基]-2-哌嗪酮
A racemic mixture of (?)-nutlin-3 and (+)-nutlin-3 -
GC17555
NVP-TNKS656
TNKS656
A TNKS2 inhibitor -
GC16179
NSC59984
A p53 reactivator
-
GC17448
AT-406 (SM-406)
AT-406; Debio 1143; SM-406
A Smac mimetic and IAP antagonist -
GC11711
ONC201
TIC10
A TRAIL-inducing compound -
GC14815
GMX1778 (CHS828)
N-[6-(4-氯苯氧基)己基]-N'-氰基-N''-4-吡啶基胍,GMX1778
A pyridyl cyanoguanidine anti-tumor agent -
GC12003
VR23
A proteasome inhibitor
-
GC16214
DEL-22379
N-[2,3-二氢-3-[(5-甲氧基-1H-吲哚-3-基)亚甲基]-2-氧代-1H-吲哚-5-基]-1-哌啶丙酰胺
An inhibitor of ERK dimerization -
GC16762
BMS-202
PD1-PDL1抑制剂2, PD-1/PD-L1 inhibitor 2
BMS-202是一种非肽性PD-1/PD-L1复合物抑制剂,与PD-L1隔离PD-1/PD-L1二聚体形成(IC50=53.6nM),以结合阻断人PD-1/PD-L1相互作用,从而抑制免疫反应抑制,从而阻止癌细胞逃避抗肿瘤免疫反应。 -
GC15399
Dp44mT
2-(二-2-吡啶基亚甲基)-N,N-二甲基肼基硫代甲酰胺
An iron chelator with antiproliferative effects -
GC17425
Sodium Tauroursodeoxycholate (TUDC)
牛磺熊去氧胆酸钠; Tauroursodeoxycholic acid sodium; TUDCA sodium; UR 906 sodium
Tauroursodeoxycholate (Tauroursodeoxycholic acid; TUDCA) sodium 是一种内质网 (ER) 应激抑制剂。 Tauroursodeoxycholate 显着降低凋亡分子的表达,例如 caspase-3 和 caspase-12。 Tauroursodeoxycholate 也抑制 ERK。 -
GC17828
BI-847325
A selective dual MEK/Aurora kinase inhibitor
-
GC16278
A-1210477
A selective Mcl-1 inhibitor
-
GC14488
NPS-1034
2-(4-氟苯基)-N-[3-氟-4-[(3-苯基-1H-吡咯并[2,3-B]吡啶-4-基)氧基]苯基]-2,3-二氢-1,5-二甲基-3-氧代-1H-吡唑-4-甲酰胺
A dual MET/AXL inhibitor -
GC16875
FLLL32
(2E,2'E)-1,1'-环己基亚基二[3-(3,4-二甲氧基苯基)-2-丙烯-1-酮]
An inhibitor of JAK2/STAT3 signaling -
GC15161
Calcium D-Panthotenate
泛酸钙; Calcium pantothenate; Calcium D-pantothenate; Vitamin B5 calcium salt
D-泛酸钙(维生素B5钙盐)是一种维生素,可以降低苹果汁中棒曲霉素的含量。 -
GC18109
Astragaloside A
黄芪甲苷
Astragaloside A(黄芪甲苷A)是从黄芪中提取的活性皂苷化合物,具有抗氧化、心脏保护、抗炎、抗病毒、抗菌、抗纤维化、抗糖尿病和免疫调节的药理作用。 -
GC10721
BDA-366
1-[[(2S)-3-(二乙基氨基)-2-羟基丙基]氨基]-4-[[(2S)-2-环氧乙烷基甲基]氨基]-9,10-蒽醌
A Bcl2-BH4 domain antagonist -
GC13442
Sanguinarine chloride
氯化血根碱; Sanguinarin chloride; Sanguinarium chloride; Pseudochelerythrine chloride
A natural alkaloid with anti-inflammatory and anti-oxidant properties -
GC12822
BML-210(CAY10433)
NphenylN'(2Aminophenyl)hexamethylenediamide, CAY10433
A potent, synthetic HDAC inhibitor -
GC17901
Tamoxifen
他莫昔芬; ICI 47699; (Z)-Tamoxifen; trans-Tamoxifen
Tamoxifen(他莫西芬)是一种选择性雌激素受体调节剂 (SERM),可阻断乳腺细胞中的雌激素作用,并可激活不同组织细胞中的雌激素活性;Tamoxifen 还可以作为 Hsp90 激活剂,增强 Hsp90 分子伴侣 ATPase 的活性;Tamoxifen 还可以诱导 CreER(T2) 小鼠的基因敲除。 -
GC12821
Oltipraz
奥替普拉; RP 35972; NSC 347901
A Nrf2 and CAR activator -
GC12074
BG45
A selective HDAC3 inhibitor
-
GC12375
PF-4989216
4-(4-氰基-2-氟苯基)-2-吗啉-5-(1H-1,2,4-三唑-5-基)噻吩-3-腈
An orally bioavailable PI3K inhibitor -
GC13219
ONO-4059
GS-4059 analog
A derivative of ONO-4059 -
GC14218
TP-0903
TP-0903
An Axl kinase inhibitor -
GC12387
Tiplaxtinin(PAI-039)
ALPHA-氧代-1-(苯基甲基)-5-[4-(三氟甲氧基)苯基]-1H-吲哚-3-乙酸,PAI-039; Tiplasinin
A PAI-1 inhibitor -
GC14681
Nolatrexed (AG-337)
盐酸诺拉曲塞,AG 337; Thymitaq
A thymidylate synthase inhibitor -
GC13526
Spautin-1
Spautin-1抑制剂
An autophagy inhibitor -
GC16827
ELR510444
An inhibitor of tubulin polymerization
-
GC14644
SBE 13 HCl
A potent Plk1 inhibitor
-
GC12222
Pexidartinib (PLX3397)
培西达替尼,PLX-3397
Pexidartinib(PLX3397) 是一种口服小分子酪氨酸激酶抑制剂,对集落刺激因子 1(CSF1) 受体 (IC50=20nM)、KIT 原癌基因受体酪氨酸激酶 (KIT)(IC50 = 10nM) 和类 FMS 酪氨酸激酶 3Pexidartinib 在体外是一种比伊马替尼更强的 KIT 抑制剂。 -
GC15654
SBI-0206965
SBI-0206965,这种嘧啶衍生物是一种高选择性的激酶ULK1抑制剂,IC50值为108nM。
-
GC11140
Radotinib(IY-5511)
拉多替尼
A selective Bcr-Abl tyrosine kinase inhibitor -
GC16310
FTI 277 HCl
FTI 277 HCl 是法尼基转移酶 (FTase) 的抑制剂;一种高效的 Ras CAAX 肽模拟物,可拮抗 H-和 K-Ras 致癌信号传导。
-
GC17916
Poziotinib
波齐替尼
An inhibitor of EGFRs -
GC14707
Purvalanol A
NG-60
A selective inhibitor of cyclin-dependent kinases -
GC10093
LY2409881
IKK2抑制剂(LY2409881)
A selective IKK2 inhibitor -
GC11547
MI-773 (SAR405838)
MI-77301
An inhibitor of MDM2-p53 protein-protein interactions -
GC16208
HO-3867
A selective STAT3 inhibitor
-
GC13474
Garcinol
山竹子素
Garcinol是组蛋白乙酰转移酶p300和PCAF的非特异性抑制剂,IC50分别为7μM和5μM。
-
GC15896
Z-Ile-Leu-aldehyde
Z-IL-CHO; GSI-XII; γ-Secretase inhibitor XII
Z-Ile-Leu-aldehyde (Z-IL-CHO) 是一种有效的、竞争性的 γ-分泌酶和缺口肽醛抑制剂。 -
GC17008
(+)-Apogossypol
變棉子酚,Apogossypol; NSC736630
(+)-Apogossypol 是一种泛 BCL-2 拮抗剂。 (+)-Apogossypol 与 Mcl-1、Bcl-2 和 Bcl-xL 结合,EC50 分别为 2.6、2.8 和 3.69 μM。
-
GC12902
Pyridoclax
MR-29072
Pyridoclax 是一种潜在的 Mcl-1 抑制剂。